尿液外泌体mRNA检测用于肾移植排斥反应的检测与风险分层
该研究开发了基于4基因特征(IL32、B2M、CXCL11、PGK1)的尿液外泌体mRNA检测ExoTRU,在226份临床指征活检配对的尿样中区分排斥或显著炎症的灵敏度为94%、阳性预测值62%、特异度52%。独立验证队列AUC为0.838,另一6基因特征区分TCMR与ABMR的AUC为0.756,可减少45%不必要的活检。
要点
- 4基因尿液外泌体mRNA特征可高灵敏度识别排斥或显著炎症,减少不必要活检。
- 特征阳性但活检阴性者5年内不良结局风险近两倍,提示活检局限性。
- 6基因特征可区分TCMR与ABMR,AUC为0.756。
核心结论
- 尿液外泌体mRNA基因特征可识别不同阶段和类型的排斥反应,包括早期和显著炎症,改善决策并减少45%不必要的活检。
研究设计与样本
- 开发适合临床实验室的工作流程,允许较小尿量和标准化qPCR仪器;共纳入214例患者的226份尿样与临床指征活检配对。
- 在独立验证队列中评估了4基因特征的性能,并评估了6基因特征区分TCMR与ABMR的能力。
主要发现
- 4基因特征(IL32、B2M、CXCL11、PGK1)区分排斥或显著炎症与无炎症的灵敏度为94%,阳性预测值62%,特异度52%。
- 特征阳性但活检阴性的患者在5年随访中发生不良结局(包括后续排斥)的可能性近两倍。
- 独立验证队列中4基因特征AUC为0.838;6基因特征区分TCMR与ABMR的AUC为0.756。
关键数值与推荐
- 4基因特征区分排斥或显著炎症的灵敏度94%、阳性预测值62%、特异度52%。
- 独立验证队列4基因特征AUC为0.838;6基因特征区分TCMR与ABMR的AUC为0.756。
- 该检测可减少45%不必要的活检。
临床怎么用
- 可用于临床指征活检前的无创风险评估,高灵敏度有助于排除显著炎症,减少不必要的活检。
- 特征阳性但活检阴性的患者应加强随访,因其5年内不良结局风险近两倍。
- 6基因特征可辅助区分TCMR与ABMR,指导个体化管理。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We recently discovered 2 urinary exosomal mRNA signatures to identify and differentiate T-cell-mediated rejection (TCMR) from antibody-mediated rejection (ABMR) in kidney transplant recipients. Here, we developed Exosome Transplant Rejection Urine (ExoTRU), a urinetest based on a 4-gene signature from the previous discovery cohort, showed its clinical utility in a new cohort of kidney transplant recipients undergoing clinically indicated biopsies, and validated it through a separate laboratory in an independent-cohort of patients. METHODS: A workflow suited for clinical laboratories was developed, allowing for smaller urine volumes and widely standardized qPCR instrumentation. A total of 226 urine samples from 214 patients were paired with clinically indicated biopsies. Urinary exosomal mRNAs levels were evaluated for previously defined targets. RESULTS: Four mRNAs (IL32, B2M, CXCL11, and PGK1) performed well in distinguishing biopsies with rejection or significant inflammation from those without inflammation, achieving 94% sensitivity, 62% positive predictive value, and 52% specificity. Patients who tested positive by the signature but negative by biopsy were nearly twice as likely to experience adverse outcomes in the 5-year follow-up period, including subsequent rejection, thereby showing the limitations of kidney biopsies and the prognostic potential of molecular signatures. The evaluation of an independent validation cohort showed similar performance, achieving an area under the curve (AUC) of 0.838. Another 6-gene signature distinguished TCMR from ABMR, with an AUC of 0.756. CONCLUSION: Exosomal mRNA gene signatures identified patients with different stages and classes of rejection, including early stage and significant inflammation, enabling improved decision-making and patient management and reducing unnecessary biopsies by 45%. This represents a potential tool for risk stratification based on poor outcomes in patients with positive signatures.
引用
- El Fekih R, Franzen K, Hurley J, et al. An Exosomal mRNA Urine Test for Detection and Risk Stratification of Human Kidney Transplant Rejection. Kidney Int Rep. 2025. PMID: 40303229. doi:10.1016/j.ekir.2025.01.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。